Vivos Therapeutics, Inc. (VVOS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 8M 16M 24M Q3 '24: 14.6M Q4 '24: 15M Q1 '25: 14.6M Q2 '25: 14.4M Q3 '25: 17.3M Q4 '25: 17.4M Q1 '26: 19.6M Q2 '26: 20.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 5M 10M 15M Q3 '24: 9M Q4 '24: 9M Q1 '25: 8.6M Q2 '25: 8.1M Q3 '25: 9.7M Q4 '25: 10.5M Q1 '26: 12.1M Q2 '26: 12.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Income TTM

-24M -16M -8M 0 8M 16M 24M Q3 '24: -12.5M Q4 '24: -11.2M Q1 '25: -11.3M Q2 '25: -14.2M Q3 '25: -16.3M Q4 '25: -19.9M Q1 '26: -22.6M Q2 '26: -22.6M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-27M -18M -9M 0 9M 18M 27M Q3 '24: -12.6M Q4 '24: -11.1M Q1 '25: -11.2M Q2 '25: -14.3M Q3 '25: -17.1M Q4 '25: -21.2M Q1 '26: -25M Q2 '26: -25.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 3M 6M 9M Q3 '24: 3M Q4 '24: 4.6M Q1 '25: 6M Q2 '25: 6.3M Q3 '25: 7.7M Q4 '25: 6.9M Q1 '26: 7.5M Q2 '26: 8M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q3 '24: -12.5M Q4 '24: -12.7M Q1 '25: -14M Q2 '25: -14.4M Q3 '25: -14.4M Q4 '25: -15.3M Q1 '26: -17.5M Q2 '26: -17.1M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-21M -14M -7M 0 7M 14M 21M Q3 '24: -13.1M Q4 '24: -13.3M Q1 '25: -14.5M Q2 '25: -15.7M Q3 '25: -15.4M Q4 '25: -17.6M Q1 '26: -19.7M Q2 '26: -19M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 7M 14M 21M Q1 '24: 2.3M Q2 '24: 3.2M Q3 '24: 6.6M Q1 '25: 8.6M Q2 '25: 9.1M Q3 '25: 11M Q1 '26: 14.6M Q2 '26: 17.7M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '24: -5.68 Q4 '24: -2.91 Q1 '25: -1.73 Q2 '25: -1.68 Q3 '25: -1.77 Q4 '25: -2.07 Q1 '26: -2.14 Q2 '26: -1.90 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.